{"nctId":"NCT01333592","briefTitle":"Long-term Study of KAD-1229 in Type 2 Diabetes Patients","startDateStruct":null,"conditions":["Type 2 Diabetes"],"count":136,"armGroups":[{"label":"KAD-1229","type":"EXPERIMENTAL","interventionNames":["Drug: KAD-1229"]}],"interventions":[{"name":"KAD-1229","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy\n* Age in the 20 years or over inclusive\n* HbA1c in the range of ≥ 6.5 to \\< 9%\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Patients with serious diabetic complications and other serious complications","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in HbA1c at 52 Weeks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.69"},{"groupId":"OG001","value":"-0.28","spread":"0.63"}]}]}]},{"type":"PRIMARY","title":"Incidences of Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":67},"commonTop":["Nasopharyngitis","γ-glutamyltransferase increase","Bronchitis","Upper respiratory tract inflammation","Pharyngitis"]}}}